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Abstract
Background: Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) are established causes
of HCC. HCC patients are often diagnosed late and receive palliative therapies, however, the
survival of Asian American patients with HCC treated without transplantation has not been well
studied. We reviewed our institution's experience to determine predictors and rates of survival in
Asian American HCC patients treated without transplantation.
Methods: We identified Asian American patients with HCC referred to M. D. Anderson Cancer
Center. Patients were tested for HBV and HCV. Survival curves were generated by Kaplan-Meier
method. Multivariate Cox proportional hazards regression was used to test the relationship
between prognostic factors and survival.
Results: Of 82 Asian American HCC patients, most had advanced disease (65%) and received
treatment (68%); however, only 11% had surgical resection. 94% had positive anti-HBc and 61% had
positive HBsAg. 20% had positive anti-HCV. There were no significant changes in the rates of HBV
and HCV over time. Male gender, high alpha-fetoprotein levels, and stage IV disease were
associated with shorter survival Overall median survival was 9.2 months (95% CI 6.5–11.9), and the
survival of HCV and HBV patients was not statistically different.
Conclusion:  The survival rate of Asian American patients with advanced HCC, for whom
transplantation was not available, was low. Timely hepatitis screening and interventions by primary
care physicians may be the most logical solution to reduce the burden of hepatitis-associated HCC
among Asian Americans.
Background
Hepatocellular carcinoma (HCC), one of the most com-
mon cancers worldwide, is rarely detected early and is
usually fatal within months of diagnosis. Recent reports
have shown significant increases in the incidence of HCC
in the US during the past two decades [1,2].
Chronic hepatitis B virus (HBV) and hepatitis C virus
(HCV) infections are established causes of HCC [3].
Worldwide, 53% of HCC cases are attributed to HBV and
25% are attributed to HCV [4]. Early detection and treat-
ment of HBV and HCV can lead to improved surveillance
for HCC, thus resulting in earlier detection of HCC and
Published: 4 February 2009
BMC Cancer 2009, 9:46 doi:10.1186/1471-2407-9-46
Received: 13 June 2008
Accepted: 4 February 2009
This article is available from: http://www.biomedcentral.com/1471-2407/9/46
© 2009 Hwang and Hassan; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2009, 9:46 http://www.biomedcentral.com/1471-2407/9/46
Page 2 of 11
(page number not for citation purposes)
reduction in HCC-associated mortality. Screening for
HBV and HCV is routine in Asian countries such as Japan
and other developed eastern countries with high preva-
lence of these diseases [5], but screening among Asian
Americans is currently is not widespread in the US [6].
Although Asian Americans represent only 4.8% of the US
population [7], cross-sectional studies from screening
events in large metropolitan areas with significant Asian
American communities indicate that the prevalence of
chronic HBV among Asian Americans is 8.9% to 15%,
making Asian Americans the racial or ethnic group with
the highest HBV prevalence in the US [8-10]. However,
the true prevalence of chronic HBV among Asian Ameri-
cans remains unclear because population-based studies
have included only small numbers of Asian Americans.
Information on the prevalence of HCC among Asian
Americans is sparse. A large retrospective study at an
urban hospital in California estimated the prevalence of
HCV among Asian Americans to be approximately 8%
[11]. Globally, the incidence of HCC is increasing in
many countries, and this has been attributed to an
increase in HCV-related HCC [12,13].
When HCC is detected early, it can be treated with curative
modalities, including liver transplantation and hepatic
resection. Tumor resectability has been shown to be an
independent predictor of improved survival among
patients with HCC [14]. However, most patients with
HCC are diagnosed at a late stage and are not candidates
for radical, curative therapies [15]; they are treated instead
with palliative treatments such as systemic chemotherapy,
arterial chemoembolism, or hormonal therapy. Previous
studies have examined clinical outcomes of Asian Ameri-
can patients with HCC, but these studies have included
patients for whom transplantation was an option [16-18].
The survival of Asian American patients with HCC treated
without transplantation has not previously been
described. At our tertiary cancer center, we do not offer
liver transplantation, and most patients with HCC receive
palliative therapies.
A previous study of Asian Americans with HCC has shown
that HBV infection predicts decreased survival [18]
whereas another study showed that hepatitis infection did
not affect survival [17]. To better understand the impact of
chronic HBV and HCV on Asian American patients with
advanced HCC, we reviewed our institution's experience
to determine the predictors and rates of survival in Asian
American HCC patients treated without transplantation.
Methods
Patient population
Using the tumor registry of The University of Texas M. D.
Anderson Cancer Center, we obtained a list of all patients
who reported themselves as being of Asian American eth-
nicity with a diagnosis of HCC who presented at M. D.
Anderson Cancer Center between January 1992 and
December 2005. All patients had a liver biopsy which
showed pathologic confirmation of HCC. This retrospec-
tive research protocol was reviewed and approved by the
M. D. Anderson institutional review board which granted
a waiver of informed consent.
The identified patients' medical records were reviewed for
demographic, clinical, and risk factor information. Struc-
tured data were collected from forms that are used to col-
lect data from patients during their first visit to M. D.
Anderson and are kept as part of the medical record. These
forms have been validated by the Departments of Epide-
miology and Gastrointestinal Medical Oncology at M. D.
Anderson. In addition to demographic information, these
forms include detailed questions on smoking, alcohol
use, family history of cancer, and medical history. For this
study, use of alcohol was defined as the consumption of
at least 4 drinks monthly for 6 months.
At M. D. Anderson, all patients with a diagnosis of HCC
are examined by a hepatobiliary oncologist for signs of
cirrhosis, such as manifestations related to portal hyper-
tension (e.g., ascites, bleeding from esophageal varices,
and hepatic encephalopathy); palmar erythema; spider
angioma; and finger clubbing. Records of these examina-
tions, plus pathologic assessments and computed tomog-
raphy scans, were reviewed for evidence of liver cirrhosis.
The patients' medical records were also reviewed for infor-
mation on hepatitis status. All patients had been tested for
the presence of antibody to hepatitis C virus (anti-HCV),
hepatitis B surface antigen (HBsAg), and antibody to hep-
atitis B core antigen (anti-HBc) with a second-generation
enzyme-linked immunosorbent assay (Abbott Laborato-
ries, North Chicago, IL), and samples yielding a positive
test result were tested three times to confirm the results.
Statistical methods
Descriptive statistics were used to compare the proportion
of demographic and clinical factors between HBV-infected
patients with and without HCV infection. SPSS (SPSS,
Inc., Chicago, IL, 2003) was used for all data management
and statistical analysis. Baseline laboratory markers were
expressed as medians. Survival curves were generated by
the Kaplan-Meier method, and the statistical significance
of potential differences between groups was determined
by using Gehan's modification of the Wilcoxon signed-
rank test. Multivariate Cox proportional hazards regres-
sion was used to test the relationship between variousBMC Cancer 2009, 9:46 http://www.biomedcentral.com/1471-2407/9/46
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prognostic factors and survival in all patients. Only those
variables showing a statistically significant (p ≤ 0.05) rela-
tionship with survival in univariate analyses were
included in the overall multivariate Cox model. The vari-
ables tested included age, sex, the presence or absence of
cirrhosis, serologic evidence of HBV or HCV infection,
comorbid conditions, and stage of HCC, previous treat-
ment, and family history of cancer. Alpha-fetoprotein
level, pathologic tumor type, and alcohol and tobacco use
were also included. The assumptions of the Cox regres-
sion analyses were verified, and all reported p values were
from two-sided tests.
Results
Patient characteristics
From January 1992 through December 2005, 82 Asian
Americans with HCC were referred to M. D. Anderson.
Overall, these patients represented 10% of all patients
with HCC referred to M. D. Anderson during the study
period. Most (81.1%) of the Asian American patients with
HCC were residents of the US. Other demographic charac-
teristics of the subjects are shown in Table 1. Mean age ±
standard deviation was 57.8 ± 12.4 years, and the male-to-
female ratio was greater than 2:1. Most of the patients
(74.3%) were originally from Vietnam, China, or Korea.
About 43% were not proficient in the English language
during the clinical visits and needed language assistance.
Thirty-eight patients (46%) were referred to M. D. Ander-
son between 1992 and 1998, and 44 (54%) were referred
between 1999 and 2005.
Clinical characteristics are shown on Table 2. The majority
of patients had advanced-stage HCC and significant liver
damage. Most patients had stage IV disease at the time of
their initial presentation to M. D. Anderson, and 21% had
stage IVB disease (distant metastases). Most patients had
alpha-fetoprotein levels of at least 100 ng/mL, and 46%
had cirrhosis. Nearly two thirds (68.4%) of the patients
ever received therapy for HCC either prior to or at M. D.
Anderson, but only 11% (n = 9) had surgical resection at
M. D. Anderson.
Rates of chronic HBV and HCV infection
The majority of patients (n = 77, 93.9%) had evidence of
previous exposure to HBV as demonstrated by a positive
HBsAg (n = 50, 61%) or an isolated positive anti-HBc (n
= 27, 32.9%) test result (Table 2). 63 patients had prior
infection with HBV alone, as evidence by a positive HBsAg
or anti-HBc test result, and did not have HCV. Sixteen
HCC patients (19.5%) were infected with HCV as indi-
cated by a positive anti-HCV test result, where 2 patients
were infected with HCV alone, and 14 patients had dual
Table 1: Demographic Characteristics of Asian American HCC patients by HBV and HCV status
Characteristics All Patients
N = 82 (%)
1HBV+/HCV- 
N = 63 (%)
2HCV+ ± HBV+
N = 16 (%)
Age group
30–41 8 (9.8) 8 (12.7) 0
41–50 19 (23.2) 19 (30.2) 0
51–60 21 (25.6) 17 (27) 4 (25)
61–70 19 (23.2) 11(17.5) 6 (37.5)
>70 15 (18.3) 8 (12.7) 6 (37.5)
Sex
Male 57 (69.5) 47 (74.6) 9 (56.3)
Female 25 (30.5) 16 (25.4) 7 (43.8)
Country of origin
Cambodia 1 (1.2) 1 (1.6) 0
China 13 (15.9) 10 (15.9) 2 (12.5)
Hong Kong 4 (4.9) 3 (4.8) 0
Korea 13 (15.9) 11 (17.5) 2 (12.5)
Philippines 6 (7.3) 6 (9.5) 0
Taiwan 8 (9.8) 6 (9.5) 2 (12.5)
Thailand 2 (2.4) 2 (3.2) 0
Vietnam 35 (42.7) 24 (38.1) 10 (62.5)
Use of English translator
Yes 35 (42.7) 21 (33.3) 12 (75)
No 47 (57.3) 42 (66.7) 4 (25)
1HBV+/HCV- represents patients with HBsAg+/anti-HBc+/anti-HCV- or HBsAg-/anti-HBc+/anti-HCV-
2HCV+ ± HBV+ represents patients with anti-HCV+/HBsAg-/anti-HBc-, anti-HCV+/HBsAg-/anti-HBc+, or anti-HCV+/HBsAg+/anti-HBc+BMC Cancer 2009, 9:46 http://www.biomedcentral.com/1471-2407/9/46
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infection with HBV and HCV. Due to small numbers,
these 16 patients are classified together as HCV+ with or
without HBV (Tables 1, 2). For clarity, these 16 patients
will be referred to as HCV+ patients in the text. Three
patients had no evidence of hepatitis infection.
The proportion of HCC patients infected with HBV infec-
tion alone was similar among patients presenting in
1992–1998 (n = 30, 83.3%) compared to those present-
ing in 1999–2005 (n = 33, 76.7%, p = 0.33) (Figure 1).
Though numbers are small, the proportion of HCC
patients with HCV infection may have increased slightly
over time, from 16.7% in 1992–1998 to 23.3% in 1999–
2005, but this difference was not significant (p = 0.58). A
slightly higher proportion of HCC patients infected with
HCV was observed among patients older than 50 years
than among younger patients, particularly in the later
period (1999–2005) (Figure 2). A substantial majority of
Asian American patients with HCC were also infected
with HBV, and this was true across all age groups and dur-
ing both time intervals (Figures 1 and 2).
Table 2: Clinical and Epidemiological Characteristics of Asian American HCC patients
Characteristics All Patients
N = 82 (%)
1HBV+/HCV-
N = 63 (%)
2HCV+ ± HBV+
N = 16 (%)
TNM stage
I or II 11 (13.4) 6 (9.7) 4 (25)
III 18 (22.0) 13 (21) 5 (31.3)
IV 53 (64.6) 43 (69.3) 7 (43.8)
Ever treated 55 (67.1) 43 (68.3) 11 (68.8)
Treatment type at M. D. Anderson Cancer Center
None 32 (39.1) 25 (39.7) 5 (31.3)
Chemotherapy 39 (47.6) 29 (46) 9 (56.3)
Surgery 4 (4.9) 4 (6.3) 0
Chemotherapy & surgery 5 (6.1) 3 (4.8) 2 (12.5)
Other 2 (2.4) 2 (3.2) 0
Cirrhosis 38 (46.3) 28 (44.4) 10 (62.5)
AFP level (ng/mL)
< 100 29 (35.4) 21 (35) 7 (46.7)
≥ 100 53 (64.6) 39 (65) 8 (53.3)
3Tumor differentiation
Well/Moderately differentiated 67 (82.7) 50 (80.6) 14 (87.5)
Poorly differentiated 13 (16.0) 11 (17.7) 2 (12.5)
4HCC risk factors
Diabetes mellitus 9 (11.0) 6 (9.8) 3 (18.8)
Cigarette smoking 36 (43.9) 28 (45.9) 8 (50)
Alcohol use 28 (34.1) 20 (32.8) 8 (50)
Family history of cancer 42 (51.2) 34 (55.7) 6 (37.5)
Family history of liver cancer 18 (22.0) 17 (27.9) 1 (6.3)
HBV/HCV status
None 3 (3.7) ___ ___
HBsAg+/anti-HBc+/anti-HCV- 48 (58.5) ___ ___
HBsAg-/anti-HBc+/anti-HCV- 15 (18.3) ___ ___
HBsAg-/anti-HBc-/anti-HCV+ 2 (2.4) ___ ___
HBsAg-/anti-HBc+/anti-HCV+ 12 (14.6) ___ ___
HBsAg+/anti-HBc+/anti-HCV+ 2 (2.4)
1HBV+/HCV- represents patients with HBsAg+/anti-HBc+/anti-HCV- or HBsAg-/anti-HBc+/anti-HCV-
2HCV+ ± HBV+ represents patients with anti-HCV+/HBsAg-/anti-HBc-, anti-HCV+/HBsAg-/anti-HBc+, or anti-HCV+/HBsAg+/anti-HBc+
3The N for tumor differentiation does not equal total number because of missing data for one HBV+/HCV- patient.
4The N for HCC risk factors does not equal total number because of missing data for 2 HBV+/HCV- patients.BMC Cancer 2009, 9:46 http://www.biomedcentral.com/1471-2407/9/46
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Patient characteristics by hepatitis status
HCC patients with HBV infection were younger than HCC
patients with HCV infection; 87.3% of the HBV patients
were 41 to 60 years of age, whereas 75% of the HCV
patients were 61 years of age or older (Table 1). HBV
patients were also more likely to present with stage IV dis-
ease (69.3% vs. 43.8%) and had higher rates of not receiv-
ing any treatment (39.7% vs. 31.3%) than patients
infected with HCV. As expected, more HCV patients had
cirrhosis (62.5% vs. 44.4%). In both the HBV and HCV
groups, high proportions of patients described their coun-
try of origin as Vietnam. Three-fourths of the HCV
patients needed translation services, compared with 33%
of the HBV patients (Table 1).
Prevalence of other known risk factors for HCC
Table 2 shows the distribution of the other major risk fac-
tors for HCC, besides hepatitis, in this highly selected
population. Overall, more than half of the patients in this
study had a family history of cancer, which may have
included a first- or second-degree relative with HCC. HCV
patients had higher rates of diabetes mellitus, cigarette
smoking and alcohol use.
Survival outcomes
Overall, median survival time for all patients was 9.2
months (95% confidence interval [CI], 6.5–11.9). HCC
patients with HCV infection had median survival of 17.3
months (95% CI, 1.1–33.5), while HCC patients with
chronic HBV alone had median survival of 7 months
Proportions of patients with HCC whose disease was associated with HCV or HBV by era of initial presentation Figure 1
Proportions of patients with HCC whose disease was associated with HCV or HBV by era of initial presenta-
tion. HBV+/HCV- represents patients with HBsAg+/anti-HBc+/anti-HCV- or HBsAg-/anti-HBc+/anti-HCV-. HCV+ ± HBV+ repre-
sents patients with anti-HCV+/HBsAg-/anti-HBc-, anti-HCV+/HBsAg-/anti-HBc+, or anti-HCV+/HBsAg+/anti-HBc+.BMC Cancer 2009, 9:46 http://www.biomedcentral.com/1471-2407/9/46
Page 6 of 11
(page number not for citation purposes)
(95% CI, 4.6–9.4) (Figure 3), but this difference was not
significant (p = 0.09).
Patients with early-stage HCC who underwent surgical
resection of the tumor alone at our institution survived
the longest (median survival time, 34.6 months; 95% CI,
14.2–52.4); those treated with chemotherapy only at our
institution had a median survival time of 8.9 months
(95% CI, 6.1–11.7). Adding chemotherapy to surgery did
not significantly extend survival relative to that after sur-
gery only. Patients never treated for HCC had the shortest
mean survival time: 4.8 months (95% CI, 2.8–6.8) (Figure
4).
Multivariate analysis of predictors of survival
Results of multivariate Cox regression analyses to identify
significant (p ≤ 0.05) predictors of survival are shown in
Table 3. We found that males with HCC were 2.4 times as
likely to die than females (95% CI = 1.2 – 4.8, p = 0.02).
HCC patients with high alpha-fetoprotein levels (≥ 100
ng/mL) were 2.6 times as likely to die than patients with
alpha-fetoprotein levels <100 ng/ml (95% CI = 1.4–4.9, p
= 0.003). In addition, patients with stage IV disease were
5.6 times as likely to die than patients with stage II or III
disease (95%CI = 2–15.3, p = 0.001). Conversely, patients
who had received any kind of treatment for HCC prior to
or at M. D. Anderson ("ever treated") had an 80% reduc-
tion in the risk of death compared with no treatment
(95% CI = 0.1–0.4, p = 0.00). We examined the effect of
different categories of treatments (chemotherapy, surgery,
and other therapies) on survival, but we found no mean-
ingful change to the positive survival effect of "ever
treated" in our model (data not shown.)
Discussion
In our series of 82 Asian Americans with HCC treated
without transplantation at our tertiary cancer center
between 1992 and 2005, we found that the rate of chronic
Proportions of patients with HCC whose disease was associated with HCV or HBV by age group and era of presentation Figure 2
Proportions of patients with HCC whose disease was associated with HCV or HBV by age group and era of 
presentation. HBV+/HCV- represents patients with HBsAg+/anti-HBc+/anti-HCV- or HBsAg-/anti-HBc+/anti-HCV-. HCV+ ± 
HBV+ represents patients with anti-HCV+/HBsAg-/anti-HBc-, anti-HCV+/HBsAg-/anti-HBc+, or anti-HCV+/HBsAg+/anti-HBc+.BMC Cancer 2009, 9:46 http://www.biomedcentral.com/1471-2407/9/46
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HBV infection was high, at 61%. The rate of chronic HCV
infection was significantly lower, at approximately 20%.
The prevalence of other risk factors for HCC, such as ciga-
rette use and alcohol abuse, was high, especially among
patients with HCV. Survival outcomes were poor overall
and in the HBV and HCV subgroups. The major predictors
of worse survival were male sex, high alpha-fetoprotein
levels, stage IV disease, and lack of treatment for HCC.
Nearly 94% of the patients in our study had previous HBV
infection, as evidenced by a positive anti-HBc test result,
and 61% of the patients had chronic HBV, as indicated by
HBsAg seropositivity. The rate of chronic HBV in our
study was lower than the 80% rate reported in a previous
study by Hwang et al. of 79 Asian American HCC patients
in California [17]. The higher rate of chronic HBV in that
study may reflect the overall higher prevalence of chronic
HBV among the Asian American population in California,
reported to be as high as 8.9% [10]. Our cancer center is a
tertiary referral center and sees cancer patients referred
from various areas: about 58% are from Texas, 39% are
from other states in the US, and 3% are international
patients (unpublished institutional data). In another
study of 220 Asian and Pacific Islander HCC patients in
Kaplan-Meier survival curves for patients with HBV and HCV Figure 3
Kaplan-Meier survival curves for patients with HBV and HCV. HBV+/HCV- represents patients with HBsAg+/
anti-HBc+/anti-HCV- or HBsAg-/anti-HBc+/anti-HCV-. HCV+ ± HBV+ represents patients with anti-HCV+/HBsAg-/anti-
HBc-, anti-HCV+/HBsAg-/anti-HBc+, or anti-HCV+/HBsAg+/anti-HBc+. Median survival is indicated.
HCV+ ± HBV+ = 17.3 months (95%CI, 1.1-33.5)  
HBV+ / HCV- = 7 months (95%CI, 4.6-9.4)  
Wilcoxon P=0.09 BMC Cancer 2009, 9:46 http://www.biomedcentral.com/1471-2407/9/46
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Hawaii, where the prevalence of chronic HBV may be less
than 2% [19], Wong et al. reported that approximately
50% of the study patients had HBV [18], similar to the
chronic HBV rate in our study (although the specific HBV
test used in the Wong et al. study was not stated).
Our study also showed that the proportion of Asian Amer-
ican HCC patients with previous HBV did not decrease
over time. This finding contrasts with the results of a study
by Hassan et al., who studied 359 HCC patients seen at
our institution during a similar period, 1993–1998, and
found that the rate of previous HBV infection decreased
over time [20]. Hassan et al. reported HBV infection rates
for the overall group and did not break down results by
ethnicity [20]. Given the paucity of population-based sur-
veillance data describing HBV infection rates in the
United States, our finding of no change in the rate of
chronic HBV infection among Asian Americans with HCC
has important implications in terms of interventions to
reach this underserved group. All Asian Americans must
be offered cost-effective HBV screening and vaccination
[21]. New and effective anti-HBV medications are availa-
ble [22,23], and patients found to have chronic HBV must
have close surveillance and be considered for treatment.
We believe that primary care physicians are the most log-
ical solution to reduce the burden of HBV-associated HCC
among Asian Americans because primary care physicians
can institute systematic and cost-effective hepatitis screen-
ing and treatment for Asian Americans [21].
Kaplan-Meier survival curves stratified by treatment exposure at M. D. Anderson Cancer Center Figure 4
Kaplan-Meier survival curves stratified by treatment exposure at M. D. Anderson Cancer Center. Median sur-
vival is indicated in parentheses.
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Although HCV is not the most prevalence risk factor for
HCC, our study adds support to the body of evidence
indicating that HCV is an important risk factor for HCC
among Asian Americans, especially for individuals who
do not have chronic HBV. Although our numbers are
small, our study revealed the rate of HCV infection to be
20% among Asian American HCC patients, of whom 88%
had a negative HBsAg test result. In the previously men-
tioned study by Hwang et al. in California, 20% of the
Asian American HCC patients had a positive HCV result,
and most of these patients (69%) had no evidence of HBV
[17].
Since the observed prevalence of HBV among patients in
our study was high, it is likely that Asian American
patients with HCC are relatively less affected than other
patients with HCC by other HCC risk factors, such as HCV
infection, cigarette smoking, alcohol, and diabetes.
Results from our ongoing case-control study where new
HCC patients are prospectively enrolled [24,25] indicate
that non-Hispanic whites are more exposed to non-virus
risk factors than Asian Americans. For example, the preva-
lence of cigarette smoking, alcohol drinking, and diabetes
mellitus among non-Hispanic whites with HCC was
70.4%, 69.4%, and 31.3%, respectively. In our study of
Asian American patients with HCC, we found the preva-
lence of these non-virus risk factors to be lower – 43.9%,
34.1%, and 11%, respectively. Our study findings were
similar to those reported previously for Asian HCC
patients in Hawaii (32% rate of alcohol use and 48% rate
of cigarette use) [18]. Diabetes mellitus, however, was
more prevalent in the Hawaii study (29%) than in our
study, and this is likely due to the significant prevalence of
diabetes in Hawaii, reported to be approximately 6% [26].
It has been shown that the Asian and Pacific Islander pop-
ulation in Hawaii is twice as likely to be diagnosed with
diabetes as US Caucasians [27].
The median survival rate in our study of Asian American
HCC patients, for whom transplantation was not availa-
ble and most of whom received palliative therapy, was
very poor: 9.2 months. This is lower than the median sur-
vival time of 1.56 years reported by Wong et al. in their
study of Asians and Pacific Islanders in Hawaii [18]. The
difference may be attributed to the higher proportion of
stage IV disease in our study (61%) than in Wong et al.'s
study (32%). The stage of disease at presentation influ-
ences whether surgical options are available. Only 11% of
the patients in our study had surgical resection; in con-
trast, in the study of Wong et al. [18], 54% of patients had
stage I or II disease, and 24% of patients underwent liver
resection and 7% liver transplantation. This supports the
notion that patients with earlier-stage disease treated with
surgical treatment options have more favorable survival
outcomes [14,15]. Similarly, in a study of 255 HCC
patients by Barazani et al. [16] in which 18% of patients
with HBV-associated HCC had liver transplantation, the
1-year survival rate was 85%, significantly higher than our
1-year survival rate of approximately 40%. Once HCC is
advanced and transplantation is no longer an option, sur-
vival is poor.
We believe that our study is the only one to date to exam-
ine the impact of treatment, excluding liver transplanta-
tion, on the survival of Asian American HCC patients. We
found that having received any type of palliative therapy
or even liver resection was a predictor of longer survival.
This again illustrates that it is critical to implement HBV
screening, surveillance, and treatment programs for Asian
Americans to ensure that if HCC develops, it will be
Table 3: Predictors of Survival: Cox Regression Multivariate Analysis
Variable Hazard Ratio 95% Confidence Interval p value
Age 0.9 0.9 – 1.02 0.5
Male sex 2.4 1.2 – 4.8 0.02
Cirrhosis 0.9 0.6 – 1.8 0.9
Moderately differentiated tumor 1.9 0.9 – 4.0 0.1
Poorly differentiated tumor 1.1 0.4 – 2.9 0.9
HBsAg+ 1.4 0.7 – 3.1 0.4
anti-HBc+ 0.7 0.2 – 2.1 0.5
anti-HCV+ 1.1 0.4 – 2.5 0.9
Diabetes 1.02 0.5 – 2.3 0.9
Alcohol use 0.6 0.3 – 1.3 0.2
Cigarette smoking 0.6 0.3 – 1.2 0.2
Family history of cancer 0.9 0.5 – 1.6 0.8
Ever treated 0.2 0.1 – 0.4 0.000
AFP ≥ 100 2.6 1.4 – 4.9 0.003
TNM stage III 2.1 0.7 – 6.02 0.2
TNM stage IV 5.6 2.0 – 15.3 0.001BMC Cancer 2009, 9:46 http://www.biomedcentral.com/1471-2407/9/46
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detected early, when curative therapy options are still
available.
Our study also found that elevated alpha-fetoprotein lev-
els and stage IV disease were associated with shorter sur-
vival. These findings are similar to findings of Wong et al.
[18]. However, whereas we found that chronic HBV was
not a significant predictor of survival, Wong et al. found
that chronic HBV was associated with worse survival [18].
It is unclear which HBV screening test(s) were used to
define HBV disease in the Wong et al. [18] study, and dif-
ferences in the testing methods may have contributed to
the survival differences. Our study does support a previ-
ous finding by Hwang et al. [17], who described no signif-
icant survival differences between HCC patients with
chronic HBV (positive HBsAg) and HCC patients with
HCV (positive anti-HCV).
The proportion of patients in our study who had a history
of alcohol use, 35%, is similar to the prevalence of 32%
reported for Asian HCC patients by Wong et al. [18].
However, in our study, alcohol use was not a significant
predictor of survival, whereas in the Wong et al study, it
was [18]. The difference may be due to the definition of
alcohol use. We defined alcohol use as at least 4 drinks
monthly for 6 months during the patient's lifetime,
whereas Wong et al. defined alcohol use as 2 drinks daily
for 10 years.
We acknowledge that our study had limitations, including
its retrospective nature and small sample size. Our study
population represents various subcategories of Asian eth-
nic groups, and their prevalences may be unique because
of their country of origin. In addition, the small number
of Asian American HCC patients with HCV is problem-
atic, and the related results discussed above should be
interpreted with caution. Our institution is a referral
center, and it may be difficult to retrospectively ascertain
full details of previous treatments that referred patients
received. Similarly, we may have underestimated the sur-
vival lengths because our analysis began with the treat-
ments at M. D. Anderson; however, we think that this
effect is likely minimal since our referral waiting periods
are not lengthy. In addition, we think that our study may
have underestimated the true effect of HBV, as we did not
specifically examine patients with an isolated positive
anti-HBc test result. Some such patients may have an
undetectable level of HBsAg and may actually be chroni-
cally infected. However, we think that this would be a
small number [28]. We are aware that comparative studies
of the clinical significance of hepatitis and predictors of
survival in patients with HCC of different ethnicities
would be helpful and could potentially lead to future
advances in policy, practice, and research. We are cur-
rently conducting such comparative studies of patients
treated at our institution, and a longer report is planned
for the future. We are also aware that our institution's sta-
tus as a tertiary referral center may have biased our study
population as such centers may attract patients with later-
stage disease and more complex cases.
Our findings in this study have important implications for
clinical practice. We believe that primary care physicians
are the most logical medical providers to break the burden
of HBV-associated HCC among Asian Americans. We
advocate the use of cost-effective strategies developed by
Hutton et al., such as screening all Asian Americans for
HBV, treating those who have evidence of chronic HBV,
and subsequently screening and vaccinating family mem-
bers of patients found to have chronic HBV [21]. These
strategies will systematically identify patients at risk for
HCC and lead them to appropriate secondary cancer pre-
vention. We also advocate close surveillance and treat-
ment of HBV patients according to therapeutic endpoints
[23]. We anticipate that significant efforts will be neces-
sary to implement these strategies in daily clinical patient
care, and we call for collaboration among national, state,
and local community organizations since up to 25% of
Asian Americans in some parts of the country do not have
a usual place for health care, most likely because of lack of
insurance and/or other barriers [29].
In conclusion, we have shown that chronic HBV remains
a significant problem among Asian American with HCC
referred to our institution and that survival of patients
with HCC treated without transplantation at our institu-
tion is poor. Early detection of HCC is vital for surgical
options to be feasible, and systematic screening of Asian
American individuals for HBV will be crucial in improving
the outcomes of Asian American patients with HCC.
Future cost analyses and quality-of-life studies will be nec-
essary to further elucidate the burden of HCC among spe-
cial populations and the impact of screening and early
detection of this disease.
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